Status:
COMPLETED
Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome
Lead Sponsor:
Rawalpindi Medical College
Conditions:
Mi Q Wave
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome
Eligibility Criteria
Inclusion
- Patients with age 18 years and above, of both genders, diagnosed with acute coronary syndrome (as per operational definition) who were not taking statins previously.
- Patients who sign written informed consent to participate in the study.
Exclusion
- Patients who are taking either statins and/or any other drug which lower serum lipid levels, patients with a history of statin hypersensitivity, patients in whom statins are contraindicated.
- Patients who will be surgically managed will be also excluded. 3.if coronary revascularization will be planned or anticipated at the time of screening.
- Pregnant or lactating women. 5.Patients having concomitant infections which cause the rise of inflammatory markers.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT06053983
Start Date
January 1 2023
End Date
August 1 2023
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rawalpindi Medical University
Rawalpindi, Pakistan